Catalog No.
Product Name
Application
Product Information
Citations
-
E3 Ligase Ligand-Linker Conjugates
(S,R,S)-AHPC-CO-C-piperazine is a ligand-linker conjugate targeting E3 ligases. This compound facilitates the formation of protein ubiquitination complexes, making it valuable for studying protein degradation pathways and developing targeted protein degradation therapies. Its unique structure enables specific interactions with E3 ligases, providing insights into their role in various cellular processes. This reagent is instrumental in chemical biology and drug discovery applications focused on modulating ubiquitin-proteasome system functions. -
E3 Ligase Ligand-Linker Conjugate
Piperidin-4-amine-C5-O-C1-Thalidomide is an E3 ligase ligand-linker conjugate designed for use in the development of PROTACs (proteolysis-targeting chimeras). This compound facilitates targeted protein degradation by linking a substrate protein to an E3 ligase, enhancing the specificity and efficacy of the degradation process. Its utility in chemical biology makes it a valuable tool for applications in targeted drug discovery and therapeutic research. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-linker Conjugate 48 is an innovative conjugate designed to target E3 ubiquitin ligases, facilitating the development of Proteolysis Targeting Chimeras (PROTACs). This reagent enables researchers to create effective PROTACs by enhancing the ubiquitin-proteasome system's activity, allowing for the selective degradation of target proteins. Its application is crucial for studies involving targeted protein degradation and therapeutic discovery. -
E3 Ligase Ligand-linker Conjugate
(S,R,S)-AHPC-CO-C4-bromine is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications using PROTAC (Proteolysis Targeting Chimeras) technology. This compound facilitates the recruitment of specific target proteins for ubiquitination by E3 ligases, thereby promoting their subsequent degradation. Its structural features enhance the efficiency of PROTAC constructs, making it a valuable tool for studying protein dynamics and therapeutic interventions in various disease models. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-PEG3-C2-NH2 hydrochloride is a synthetic conjugate designed as an E3 ligase ligand-linker. This compound features a Thalidomide-derived cereblon ligand, effectively facilitating targeted protein degradation through PROTAC technology. It is instrumental in research applications focusing on the modulation of cellular protein levels and the exploration of E3 ligase-related pathways. -
LCL-PEG3-N3 Decoy Oligonucleotide Ligand
LCL-PEG3-N3 is a decoy oligonucleotide ligand targeting E3 ligases, facilitating the development of chimeric molecules such as LCL-ER(dec) for the degradation of estrogen receptors. As a versatile click chemistry reagent, it features an azide functional group, enabling copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules. Additionally, LCL-PEG3-N3 can participate in strain-promoted alkyne-azide cycloaddition (SPAAC) reactions when combined with DBCO or BCN-modified entities. This compound is valuable in chemical biology applications and protein degradation studies. -
CRBN Ligand
Pomalidomide-5-C8-NH2 hydrochloride is a CRBN ligand derived from Pomalidomide. This compound facilitates the recruitment of the cereblon (CRBN) protein, enabling the design of targeted protein degradation strategies. It can be conjugated with a suitable linker to create PROTACs, which are valuable tools in therapeutic applications for modulating protein levels in various biological contexts. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-C2-Br is an E3 Ligase Ligand-Linker conjugate that functions as a versatile tool for targeted protein degradation. This compound is designed to facilitate the synthesis of PROTAC AR Degrader-8, enabling researchers to investigate the modulation of protein levels via the ubiquitin-proteasome system. Its unique structure supports the development of innovative approaches for therapeutic intervention in various diseases, particularly in oncology research. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-C10-NHBoc is an E3 ligase ligand-linker conjugate that utilizes the (S,R,S)-AHPC-based VHL ligand along with a designed linker for BET-targeted PROTAC applications. This compound facilitates the selective degradation of target proteins through the recruitment of E3 ligases. Its structural design makes it a valuable tool for studies in targeted protein degradation and the development of innovative therapeutic strategies in cancer research. -
E3 Ligase Ligand-Linker Conjugate
8-Hydroxyoctanoic acid-thalidomide is an E3 ligase ligand-linker conjugate that facilitates the targeted degradation of proteins via the ubiquitin-proteasome pathway. This compound exhibits potent activities that support the development of targeted protein degradation strategies in chemical biology research. Additionally, it can be employed in the synthesis of Lw13 for further investigative studies into protein modulation and therapeutic applications. -
Ligand for E3 Ligase
Pomalidomide-C11-NH2 hydrochloride is a potent ligand targeting the E3 ubiquitin ligase cereblon (CRBN). This compound facilitates the recruitment of CRBN, enabling the development of proteolysis-targeting chimeras (PROTACs) for targeted protein degradation. Its utility in drug discovery and molecular biology research makes it a valuable tool for studying protein regulation and associated pathways. -
Von-Hippel-Lindau Pprotein Ligand
VH 101 phenol-alkylC4-amine dihydrochloride is a ligand for the von-Hippel-Lindau (VHL) protein, functioning as an E3 ligase ligand with an integrated alkylC4 linker. This compound is instrumental in proteolysis-targeting chimera (PROTAC) research, enabling targeted degradation of specific proteins to study their biological functions and implications in various diseases. Its unique design allows for enhanced modulation of protein interactions, making it a valuable tool in molecular and cellular biology research. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-Linker Conjugate 116 is designed as a ligand-linker conjugate targeting E3 ubiquitin ligases. This compound facilitates the synthesis of PROTAC SMARCA2/4-degrader-28, enabling selective protein degradation through the ubiquitin-proteasome system. Its applications are particularly significant in studying mechanisms of protein regulation and the development of targeted therapeutics in cancer research. -
E3 Ligase Ligand-Linker Conjugate
AHPC-PEG6-CH2COOH is a conjugate designed to facilitate interactions with E3 ligases, featuring a von Hippel-Lindau (VHL) ligand linked through a 6-unit polyethylene glycol (PEG) chain. This reagent serves as a valuable tool in the synthesis of PROTAC CMP98, enabling targeted protein degradation applications in chemical biology research. Its unique structure allows for improved solubility and bioavailability, making it suitable for various studies involving targeted protein modulation. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-CO-PEG3-NHBoc is an E3 ligase ligand-linker conjugate designed for the synthesis of PROTAC G9a/GLP degrader 1. This compound facilitates targeted protein degradation through the selective degradation of G9a and GLP, demonstrating significant anti-cancer activity. Its application is pivotal in advancing research in protein modulation and therapeutic development in oncology. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-C2-PEG3-NH2 is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound facilitates the synthesis of PROTACs, such as USP39 Degrader-1, enabling the selective degradation of specific protein targets through the ubiquitin-proteasome system. Its structure includes a polyethylene glycol (PEG) linker, enhancing solubility and pharmacokinetic properties for more effective biological activity in research studies. -
Multikinase Degrader
Azido-PEG2-VHL is a multikinase degrader that serves as a versatile building block for the synthesis of PROTACs (proteolysis-targeting chimeras). This compound features an azide functionality, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with alkyne-functionalized molecules, such as those containing DBCO or BCN groups. Its application in targeted protein degradation makes it a valuable tool in chemical biology research. -
E3 Ubiquitin Ligase Ligand-Linker Conjugate
Thalidomide 4'-ether-PEG2-azide is a click chemistry-modified derivative of Thalidomide that functions as an E3 ubiquitin ligase ligand-linker conjugate. It features an azide group capable of participating in copper-catalyzed azide-alkyne cycloaddition reactions, making it suitable for conjugation with alkynyl-containing molecules. This reagent is particularly valuable in the development of Proteolysis Targeting Chimeras (PROTACs), enabling targeted protein degradation and advanced therapeutic strategies in cancer research and other areas of drug discovery. -
E3 Ligase Ligand-Linker Conjugates
E3 Ligase Ligand-linker Conjugate 133 is a synthesized conjugate comprising an E3 ligase ligand and a linker, functioning as a crucial intermediate in the development of the PROTAC molecule pan-KRAS degrader 4. This compound facilitates targeted protein degradation by leveraging the ubiquitin-proteasome system, making it essential for studies related to targeted cancer therapeutics and protein modulation. Its application in PROTAC research highlights its potential in advancing therapeutic strategies against malignancies associated with KRAS mutations. -
E3 Ubiquitin Ligase Ligand-Linker Conjugate
Thalidomide-O-C5-azide is a specialized E3 ubiquitin ligase ligand-linker conjugate, derived from the CRBN inhibitor Thalidomide. This compound features an azide group capable of participating in copper-catalyzed azide-alkyne cycloaddition reactions, making it suitable for use in the synthesis of PROTACs. Thalidomide-O-C5-azide facilitates targeted protein degradation, making it a valuable tool in chemical biology and therapeutic research applications. -
E3 Ligase Ligand-Linker Conjugates Chemical
(S,R,S)-AHPC-Me-decanedioic acid is an E3 ligase ligand-linker conjugate that facilitates the development of proteolysis targeting chimeras (PROTACs). This compound enables targeted protein degradation by linking specific ligands to E3 ligases, supporting research into cellular regulation and therapeutic interventions. It is suitable for applications involving the modulation of protein levels in various biological systems. -
E3 Ligase Ligand-linker Conjugate
CRBN ligand-895-PEG2-N3 is a synthetic E3 ligase ligand-linker conjugate designed to facilitate the development of PROTACs. This compound plays a crucial role in the targeted degradation of proteins by linking to E3 ligases, enhancing the specificity and efficacy of degradation processes. It serves as a valuable tool for researchers investigating protein modulation and therapeutic applications in targeted protein degradation strategies. -
VHL-linker Isomer
(S,S,S)-AHPC-PEG2-NH2 is a VHL-linker isomer designed for targeted protein degradation applications. This compound serves as a component in the synthesis of PROTACs, facilitating the selective ubiquitination and degradation of target proteins. It is particularly relevant for research in leukemia and other related hematological malignancies, providing a valuable tool for investigating protein function and therapeutic potential. -
E3 Ligase Ligand-Linker Conjugates
A 410099.1 amide-PEG3-amine-Boc is a functionalized IAP ligand specifically designed for use in PROTAC technology, featuring an IAP ligand coupled with an amide-PEG3 linker that contains a terminal amine group. This compound facilitates the conjugation of target protein ligands, making it suitable for research applications involving targeted protein degradation. Its unique structure allows for enhanced specificity and efficiency in E3 ligase recruitment, contributing to advancements in therapeutic drug development and cellular biology studies. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-Linker Conjugate 166 is a specialized conjugate that combines an E3 ligase ligand with a linker, facilitating targeted protein degradation. This compound is instrumental in the synthesis of PROTAC CDK9 degrader-11, serving as a valuable tool for studying targeted degradation pathways. Its application in research contributes to the exploration of novel therapeutic strategies for modulating protein levels in various biological contexts. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-N-methylpiperazine is an E3 ligase ligand-linker conjugate that facilitates targeted protein degradation through the PROTAC (Proteolysis Targeting Chimeras) approach. This compound is employed in the synthesis of PROTAC MLKL Degrader-2, demonstrating antinecroptotic activity in human cell lines and effectively degrading MLKL in HT-29 xenograft mouse models. Its applications are pivotal in understanding necroptosis and exploring therapeutic strategies in related diseases. -
E3 Ligase Ligand-linker Conjugate
E3 Ligase Ligand-linker Conjugate 213 is a specialized linker conjugate designed to engage E3 ubiquitin ligases, specifically CRBN. This dual-functional compound combines an E3 ligase ligand with a linker, facilitating the development of targeted protein degradation strategies. Its primary applications include drug discovery and the synthesis of proteolysis targeting chimeras (PROTACs), such as PSP-0119, enhancing the modulation of protein turnover in cellular contexts. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-linker Conjugate 136 is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound facilitates the synthesis of c-Myc inhibitor 7, enabling the study of c-Myc-related signaling pathways and the development of innovative therapeutic strategies. Its unique mechanism allows for the precise modulation of protein levels, which is critical for functional assays in cancer research and other biochemical investigations. -
E3 Ligase Ligand-linker Conjugate
Pomalidomide-C9-Br is an E3 ligase ligand-linker conjugate designed for the synthesis of PROTAC EGFR degrader 15, a targeted protein degradation agent. This compound exhibits significant anti-cancer activity by promoting the degradation of epidermal growth factor receptor (EGFR) through the proteasome pathway. The use of Pomalidomide-C9-Br in research applications may accelerate the development of novel therapeutics aimed at treating EGFR-driven malignancies. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-C3-NH2 is an E3 ligase ligand-linker conjugate designed to engage cereblon, leveraging the properties of Pomalidomide. This compound facilitates the development of PROTAC (Proteolysis Targeting Chimera) strategies, enabling targeted protein degradation. Its unique composition allows for enhanced cellular uptake and efficacy in modulating protein levels, making it valuable for research in drug discovery and therapeutic applications related to protein regulation. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-C5-azacyclohexane-N-Boc is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. It facilitates the synthesis of XD2-149, enabling researchers to investigate the modulation of E3 ligase activity and its biological effects. This compound supports studies in chemical biology, therapeutic development, and the exploration of ubiquitin-proteasome system interactions. -
Ligand for E3 Ligase
Pomalidomide-5-C7-NH2 hydrochloride is a synthetic ligand targeting the E3 ligase cereblon (CRBN). This compound facilitates the recruitment of CRBN, enabling the innovative design of PROTACs (Proteolysis Targeting Chimeras) for targeted protein degradation studies. Its unique chemical structure supports the exploration of CRBN's role in various cellular processes and therapeutic applications, such as oncology and autoimmune diseases. -
Protein Ligand
Lenalidomide 4'-alkyl-C5-azide is a functionalized cerebellar ligand designed for the development of PROTACs. This compound features an E3 ligase ligand and a long-chain alkyl group with terminal azides, facilitating the conjugation with target protein ligands. It serves as an important tool for researchers investigating targeted protein degradation and related pathways in cellular models. -
E3 Ligase Ligand-Linker Conjugates
E3 Ligase Ligand-linker Conjugate 141 is a conjugate designed for interaction with E3 ubiquitin ligases, facilitating the development of proteolysis-targeting chimeras (PROTACs). This compound is integral for synthesizing PROTAC ER Degrader-12, which selectively degrades estrogen receptors. Researchers can utilize this conjugate in studies focused on targeted protein degradation and drug discovery, particularly in the context of cancer therapy and hormone-related disorders. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-amido-PEG2-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that utilizes Thalidomide as a cereblon-targeting ligand combined with a PEG-based linker. This compound is designed for applications in PROTACs (proteolysis-targeting chimeras), facilitating targeted protein degradation for therapeutic interventions. Its specific mechanisms enable the modulation of protein levels within cells, making it a valuable tool for investigating cellular pathways and developing novel treatments. -
Click Chemical Reagent
Lenalidomide 4'-alkyl-C3-azide is a click chemical reagent that incorporates an azide group into lenalidomide, facilitating the synthesis of PROTACs. As an orally active immunomodulator, lenalidomide acts as a ligand for the ubiquitin E3 ligase cereblon (CRBN). This compound is capable of undergoing copper-catalyzed azide-alkyne cycloaddition (CuAAC) reactions with alkyne-containing molecules, as well as strain-promoted azide-alkyne cycloaddition (SPAAC) with DBCO or BCN groups, thereby enabling versatile modifications in chemical biology research. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-azetidin-3-one is an E3 ligase ligand-linker conjugate that facilitates targeted protein degradation. This compound is instrumental in the synthesis of the PROTAC PD-L1 degrader-2, enabling researchers to investigate therapeutic strategies for modulating immune responses through PD-L1 degradation. Its incorporation into PROTAC design holds potential for advancing cancer immunotherapy research. -
E3 Ligase Ligand-linker Conjugate
E3 Ligase Ligand-linker Conjugate 185 is designed as a specific E3 ligase ligand-linker conjugate. This compound facilitates the development of PROTACs (Proteolysis Targeting Chimeras) by enabling targeted degradation of proteins through the recruitment of E3 ligases. Its applications extend to various fields including cancer research, pharmacology, and drug discovery, where it helps in studying protein regulation and therapeutic targeting. -
E3 Ligase Ligand-Linker Conjugate
(S,S,R)-AHPC-C6-NH2 is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound facilitates the development of proteolysis-targeting chimeras (PROTACs) by linking target proteins to E3 ligases, enhancing selective degradation pathways in cellular models. It is instrumental in advancing research in targeted therapy and studying cellular processes related to protein homeostasis. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-linker Conjugate 165 is a specialized conjugate composed of an E3 ligase ligand and a linker, designed for use in the synthesis of PROTAC SJ44236. This compound facilitates targeted protein degradation by promoting the ubiquitination of specific proteins, thereby enhancing the study of protein function and regulation in various biological contexts. Its application is crucial in the development of novel therapeutic strategies that leverage the ubiquitin-proteasome system. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-Linker Conjugate 51 is a conjugate that incorporates a Thalidomide-derived E3 ligase ligand with a linker component. This compound functions as a ligand for Cereblon, effectively facilitating the recruitment of the CRBN protein. E3 Ligase Ligand-Linker Conjugate 51 is crucial for the synthesis of complete PROTAC (Proteolysis Targeting Chimeras) molecules, making it valuable for research in targeted protein degradation and related therapeutic applications. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-PEG2-C2-boc is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound facilitates the synthesis of PROTAC YAP degrader-1, enabling efficient modulation of protein levels through the ubiquitin-proteasome pathway. It is valuable for research in targeted therapeutic strategies and the study of protein homeostasis in various biological systems. -
E3 Ligase Ligand-Linker Conjugate
BTK ligand 11-alcohol-PEG6-azido is a synthetic E3 ligase ligand-linker conjugate designed for the development of proteolysis-targeting chimeras (PROTACs). This compound facilitates the targeted degradation of proteins by linking the E3 ligase to the target protein, enhancing the specificity and efficacy of the degradation process. Its applications in research include the study of protein regulation and the modulation of cellular pathways involved in various diseases. -
E3 Ligase Ligand-Linker Conjugate
Me-Thalidomide-O-C8-NH2 is an E3 ligase ligand-linker conjugate that facilitates targeted protein degradation. This compound demonstrates key biological activity in modulating E3 ubiquitin ligase interactions, which is essential for the development of novel therapeutic strategies. It serves as a valuable intermediate in the synthesis of MS154N, contributing to research in drug discovery and cellular regulation pathways. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-linker Conjugate 58 functions as a conjugate of E3 ligase ligand and linker, incorporating Thalidomide as its ligand. This compound effectively recruits the Cereblon (CRBN) protein, making it an essential intermediate for the synthesis of complete PROTAC (proteolysis-targeting chimera) molecules. Its application in targeted protein degradation research highlights its significance in advancing therapeutic strategies in various diseases. -
E3 Ligase-Linker Conjugate
trans-Thalidomide-1,4-cyclohexanediamine is an E3 ligase-linker conjugate utilized in the synthesis of PROTACs. This compound serves as a crucial building block for developing PROTACs, such as CL-F-B1, which demonstrates potent activity in degrading PD-L1 and has significant anticancer effects. Its application in PROTAC technology facilitates targeted degradation of specific proteins, making it valuable in cancer research and therapeutic development. -
E3 Ligase Ligand-Linker Conjugates Chemical
2-(2,6-Dioxopiperidin-3-yl)phthalimidine-C5-Br is an E3 ligase ligand-linker conjugate specifically designed for use in PROTAC (Proteolysis Targeting Chimera) technology. This compound facilitates targeted proteolysis by recruiting E3 ligases, enabling the selective degradation of specific proteins within cellular environments. Its role in modulating protein levels makes it a valuable tool for research in targeted protein degradation and therapeutic applications related to cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugate
Phthalimidinoglutarimide-piperidine-NH2 is an E3 ligase ligand-linker conjugate that comprises a Thalidomide moiety. This compound functions as a Cereblon ligand, facilitating the recruitment of the CRBN protein. It plays a crucial role as an intermediate in the synthesis of complete PROTAC molecules, making it valuable for research in targeted protein degradation and therapeutic applications. -
E3 Ligase Ligand-Linker Conjugates
AhR Ligand-Linker Conjugates 1 is designed as an E3 ubiquitin ligase ligand-linker conjugate that incorporates an IAP (inhibitor of apoptosis) ligand alongside a SNIPER (Specific and Pioneering IAP-medited Protein elimination) linker. This reagent enables the targeted degradation of specific proteins through the recruitment of E3 ligases. Its applications extend to drug discovery and the study of protein regulation through the ubiquitin-proteasome system, facilitating advancements in therapeutic strategies. -
CRBN Ligand-Linker Conjugates
E3 Ligase Ligand-linker Conjugate 195 is a conjugate that targets cereblon (CRBN) through its ligand component. This compound facilitates the development of Proteolysis Targeting Chimeras (PROTACs) by providing a functional linker necessary for targeted protein degradation. It is suitable for research applications investigating novel therapeutic strategies in protein modulation and degradation pathways.
